Opinion|Videos|November 25, 2024
Navigating Systemic Therapy Options in HER2+ Breast Cancer
Panelists discuss a high-level overview of systemic therapies for advanced HER2+ breast cancer, outlining the roles of HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) in treatment, as well as treatment strategies for patients with brain metastases. They also explore the shared decision-making process that informed the recommendation of the HER2CLIMB regimen.
Advertisement
Episodes in this series
- Dr Iyengar: Please provide a high-level overview of the systemic therapies that you consider for advanced HER2+ breast cancer. (sSee
NCCN Guidelines Version 2.2024 .)
- What is the role of HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and ADCs in treating advanced HER2+ breast cancer?
- How do you typically manage treat patients with advanced HER2+ breast cancer and brain metastases?
- Following Dorian’s evaluation, how did the shared decision-making process unfold, and what factors ultimately led you to recommend the HER2CLIMB regimen (trastuzumab [Herceptin] and + tucatinib [Tukysa] and capecitabine [Xeloda])?
Advertisement
Related to this article
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
Adjuvant Ribociclib Improves OS at 6 Years in HR+/HER2- Early Breast Cancer
3
Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC
4
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
5